Eltrombopag – Thrombopoietin Receptor Agonist for Low Platelets

Eltrombopag is a small-molecule, non-peptide thrombopoietin receptor (TPO-R) agonist designed to treat conditions characterized by a critical decrease in platelet counts. The drug interacts with the transmembrane domain of the human thrombopoietin receptor, triggering intracellular signaling cascades (JAK/STAT and MAPK). This stimulates the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, leading to a physiological increase in platelet production and a reduced risk of bleeding.

The mechanism of action of eltrombopag is unique because it does not compete with endogenous thrombopoietin but instead provides an additive effect. It was the first oral medication to effectively address thrombocytopenia in chronic immune thrombocytopenia (ITP), severe aplastic anemia, and hepatitis C. Beyond stimulating thrombopoiesis, eltrombopag may positively influence all hematopoietic lineages in patients with aplastic anemia, aiding bone marrow recovery. A significant pharmacological feature is the drug's interaction with polyvalent cations (calcium, magnesium, iron), necessitating strict adherence to intake rules regarding food and dairy products. Eltrombopag helps avoid frequent platelet transfusions and significantly improves the prognosis for patients with chronic hematological diseases.

The drug is taken orally once daily. Therapy requires regular laboratory monitoring of blood counts and liver function.

Wikipedia page

Indications

Eltrombopag is indicated for the treatment of adult and pediatric patients with the following pathologies:

Chronic Immune Thrombocytopenia (ITP): treatment of patients who have had an insufficient response to corticosteroids or immunoglobulins.
Chronic Hepatitis C: treatment of thrombocytopenia in patients to enable the initiation and maintenance of interferon-based therapy.
Severe Aplastic Anemia: use as first-line therapy (in combination with immunosuppression) or in patients with an insufficient response to prior immunosuppressive therapy.

Dosage and administration

Eltrombopag dosage is individualized to achieve a platelet count that minimizes the risk of bleeding.

Starting Dose: typically 50 mg once daily (for individuals of East Asian ancestry, 25 mg).
Administration Method: the drug should be taken at least 2 hours before or 4 hours after consuming antacids, dairy products, or mineral supplements.
Dose Adjustment: the dose is titrated in 25 mg increments until the target platelet level (above 50,000/µL) is reached. Maximum dose is 75 mg (up to 150 mg for aplastic anemia).
Liver Monitoring: ALT, AST, and bilirubin levels must be measured before starting treatment and every 2 weeks during the dose titration phase.
Missed Dose: if a dose is missed, wait until the next scheduled dose; a double dose should not be taken.

The use of eltrombopag requires caution in the presence of the following risk factors:

Hypersensitivity: known allergy to eltrombopag or the tablet coating components.
Hepatic Impairment: requires a lower starting dose and extremely cautious titration.
Thromboembolic Risks: presence of risk factors for thrombosis (genetic mutations, advanced age, immobilization).
Pregnancy and Lactation: use is not recommended as the drug may cross the placenta and enter breast milk.
Myelodysplastic Syndrome (MDS): there is a risk of MDS progressing to acute myeloid leukemia.

Side effects of eltrombopag may vary depending on the patient's underlying condition:

Hepatotoxicity: increased liver enzymes and serum bilirubin levels.
Digestive System: nausea, diarrhea, vomiting, and abdominal pain.
General Symptoms: headache (very common), fatigue, and flu-like syndrome.
Ocular Effects: risk of cataract development or progression, requiring ophthalmologic monitoring.
Thrombosis: risk of forming blood clots in deep veins or the portal vein.
Muscular System: myalgia (muscle pain) and bone pain.

Frequently Asked Questions

Eltrombopag is a thrombopoietin receptor agonist. It mimics the action of the natural hormone thrombopoietin, which signals the bone marrow to produce more platelet precursor cells. As a result, the body increases the production of new platelets, helping to prevent dangerous bleeding in patients with low platelet counts.

Eltrombopag is indicated for the treatment of immune thrombocytopenia (ITP) when other therapies have failed. It is also prescribed for patients with severe aplastic anemia and to manage low platelet counts in patients with chronic hepatitis C, enabling them to initiate or maintain antiviral therapy.

Eltrombopag binds to polyvalent cations (such as calcium, magnesium, iron, and zinc). This interaction makes the drug nearly insoluble and significantly reduces its absorption in the gut. The medication must be taken at least 2 hours before or 4 hours after consuming dairy products, antacids, or mineral supplements.

The primary focus is regular monitoring of platelet counts to avoid excessive levels and the risk of thrombosis. It is also critical to monitor liver function (ALT, AST, and bilirubin), as the substance can be hepatotoxic. Blood tests are typically performed weekly during dose titration and monthly once a stable dose is established.

Abruptly stopping the medication can cause platelet counts to rapidly drop below the pre-treatment baseline. This significantly increases the risk of severe spontaneous bleeding. Any dose adjustments or cessation of treatment must be conducted under strict medical supervision and accompanied by frequent blood count monitoring.